Cited by 2,527Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Open access

Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, Ou, Sai-Hong I., Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N., Mok, Tony·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1704795

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1704795

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citation
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citation
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citation
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Ou, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citation
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
Lu S, 2016, J Clin Oncol
Hida T, Lancet

Sorted by citations

Items 701–800 of 1,000

Central Nervous System Metastases
Nieblas‐Bedolla, E., Zuccato, J., Kluger, H. M., Zadeh, G. M., & Brastianos, P. K. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.004 · Cited by 22
ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)
Li, M., Hou, X., Chen, J., Zhang, B., Wang, N., Han, H., & Chen, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.006 · Cited by 22
GUK1 activation is a metabolic liability in lung cancer
Schneider, J. L., Kurmi, K., Dai, Y., Dhiman, I., Joshi, S., Gassaway, B. M., Johnson, C. W., Jones, N., Li, Z., Joschko, C. P., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.024 · Cited by 21
Giant steps and stumbling blocks
Heigener, D. F., & Reck, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.178 · Cited by 21
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
Lin, H. M., Pan, X., Hou, P., Huang, H., Wu, Y., Ren, K., & Jahanzeb, M. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1762620 · Cited by 21
An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease
Vavalà, T., Rigney, M., Reale, M. L., Novello, S., & King, J. C. (2020) · Respirology · doi:10.1111/resp.13965 · Cited by 22
Treatment of brain metastases in ALK-positive non-small cell lung cancer
Ceddia, S., & Codacci-Pisanelli, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103400 · Cited by 23
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
Tanimura, K., Yamada, T., Okada, K., Nakai, K., Horinaka, M., Katayama, Y., Morimoto, K., Ogura, Y., Takeda, T., Shiotsu, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00250-8 · Cited by 21
Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study
Reza, R., Dutta, T., Baildya, N., Ghosh, N. N., Khan, A. A., & Das, R. K. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105615 · Cited by 22
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Soumerai, J. D., Rosenthal, A. C., Harkins, S. K., Duffy, J., Mecca, C., Wang, Y., Grewal, R. K., El-Jawahri, A. R., Liu, H., Menard, C., et al. (2022) · Blood · doi:10.1182/blood.2022015443 · Cited by 21
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
Barbieri, M. A., Sorbara, E. E., Cicala, G., Santoro, V., Cutroneo, P. M., Franchina, T., Santarpía, M., Silvestris, N., & Spina, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005626 · Cited by 21
Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease
Nelson, T. A., & Wang, N. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-638 · Cited by 21
Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform
Scorsetti, M., Navarria, P., Cozzi, L., Clerici, E., Bellu, L., Franceschini, D., Marzo, A. M., Franzese, C., Torri, V., Reggiori, G., et al. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02216-5 · Cited by 21
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
Fabbri, L., Federico, A. D., Astore, M., Marchiori, V., Rejtano, A., Seminerio, R., Gelsomino, F., & Giglio, A. D. (2023) · Diagnostics · doi:10.3390/diagnostics14010048 · Cited by 21
Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy
Yun, Y., Kim, S., Lee, S., Cho, H., & Choi, J. (2024) · Nano Convergence · doi:10.1186/s40580-024-00466-x · Cited by 21
The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients
Loganadane, G., Hendriks, L. E. L., Pechoux, C. L., & Lévy, A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.006 · Cited by 21
The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer
Gomes, F., Tay, R. Y., Chiramel, J., & Califano, R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0573-z · Cited by 22
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Acquired Resistance in Lung Cancer
Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21
Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
Sivignon, M., Monnier, R., Téhard, B., & Roze, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226196 · Cited by 21
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
Osta, B. E. E., & Ramalingam, S. S. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100050 · Cited by 21
Reference standards for gene fusion molecular assays on cytological samples: an international validation study
Malapelle, U., Pepe, F., Pisapia, P., Altimari, A., Bellevicine, C., Brunnström, H., Bruno, R., Büttner, R., Cirnes, L., de Andrea, C. E., et al. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207825 · Cited by 21
Self-citation
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC
Protopapa, M., Kouloulias, V., Nikoloudi, S., PAPADIMITRIOU, C. A., Gogalis, G., & Zygogianni, A. G. (2019) · Journal of Oncology · doi:10.1155/2019/3267409 · Cited by 21
Cellular thermal shift assay: an approach to identify and assess protein target engagement
Zhang, L., Wang, Y., Chang, Z., Zhou, Z., & Chen, Z. (2024) · Expert Review of Proteomics · doi:10.1080/14789450.2024.2406785 · Cited by 20
Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers
Malhotra, J. D., Mambetsariev, I., Gilmore, G., Fricke, J., Nam, A., Gallego, N., Chen, B. T., Chen, M. Y., Amini, A., Lukas, R. V., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5218 · Cited by 22
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
Listì, A., Barraco, N., Bono, M., Insalaco, L., Castellana, L., Cutaia, S., Ricciardi, M. R., Gristina, V., Bronte, E., Pantuso, G., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.04 · Cited by 21
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
Heo, J. Y., Park, C., Keam, B., Ock, C., Kim, M., Kim, T. M., Kim, D., Kim, S. H., Kim, Y. J., Lee, J. S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13195 · Cited by 20
Self-citation
Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era
Kehl, K. L., Hassett, M. J., & Schrag, D. (2020) · Cancer Medicine · doi:10.1002/cam4.2854 · Cited by 20
Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery
Singh, S. A., McDermott, D. M., & Mattes, M. D. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.09.082 · Cited by 20
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Zhao, Y., Wang, S., Yang, Z., Dong, Y., Wang, Y., Zhang, L., Hu, H., & Han, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665484 · Cited by 20
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer
Boosman, R. J., Burgers, J. A., Smit, E. F., Steeghs, N., van der Wekken, A. J., Beijnen, J. H., Huitema, A. D. R., & ter Heine, R. (2021) · Drugs · doi:10.1007/s40265-021-01654-3 · Cited by 20
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
Greillier, L., Gauvrit, M., Paillaud, É., Girard, N., Montégut, C., Boulahssass, R., Wislez, M., Pamoukdjian, F., Corre, R., Cabart, M., et al. (2022) · Cancers · doi:10.3390/cancers14030769 · Cited by 20
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
Luo, X., Zhou, Z., Zeng, X., Peng, L., & Liu, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.985834 · Cited by 20
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 20
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
Chazan, G., & Solomon, B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-656 · Cited by 22
Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario
Bertaglia, V., Morelli, A. M., Solinas, C., Aiello, M. M., Manunta, S., Denaro, N., Tampellini, M., Scartozzi, M., & Novello, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103954 · Cited by 20
Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers
Brozos-Vázquez, E., Rodríguez-López, C., Cortegoso-Mosquera, A., López-Landrove, S., Muinelo‐Romay, L., García, J., López‐López, R., & León‐Mateos, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221113 · Cited by 20
Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know
Serrão, E. M., Klug, M., Moloney, B., Jhaveri, A., Gullo, R. L., Pinker, K., Luker, G. D., Haider, M. A., Shinagare, A. B., & Liu, X. (2023) · Radiology Imaging Cancer · doi:10.1148/rycan.220153 · Cited by 20
Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)
Umar, H., Wahab, H. A., Attiq, A., Amjad, M. W., Bukhari, S. N. A., & Ahmad, W. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111856 · Cited by 23
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
Tanaka, H., Sase, H., Tsukaguchi, T., Hasegawa, M., Tanimura, H., Yoshida, M., Sakata, K., Fujii, T., Tachibana, Y., Takanashi, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1180 · Cited by 20
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melián, M., Lorente, D., Aparici, F., & Juan, Ó. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12873 · Cited by 20
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
Reckamp, K. L., Lin, H. M., Huang, J., Proskorovsky, I., Reichmann, W. M., Krotneva, S., Kerstein, D., Huang, H., & Lee, J. J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1520696 · Cited by 20
Ocular And Orbital Side Effects of Alk Inhibitors: A Review Article
Chelala, E., Hoyek, S., Arej, N., Kattan, J. G., Kourié, H. R., Baakliny, J., & Antoun, J. (2019) · Future Oncology · doi:10.2217/fon-2018-0608 · Cited by 20
Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use
Gougis, P., Palmieri, L., Funck‐Brentano, C., Paci, A., Flippot, R., Mir, O., & Coriat, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.006 · Cited by 21
Opportunities of circulating tumor DNA in lung cancer
Wu, T., Hsiue, E. H.-C., & Yang, J. C. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.002 · Cited by 20
Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona, A. (2019) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2019.03.009 · Cited by 22
Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020
Elkrief, A., Joubert, P., Florescu, M., Tehfe, M. A., Blais, N., & Routy, B. (2020) · Current Oncology · doi:10.3747/co.27.5953 · Cited by 21
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
Barlési, F., & Tomasini, P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30207-2 · Cited by 20
TRK Inhibitors in Non-Small Cell Lung Cancer
Harada, G., Gongora, A. B. L., da Costa, C. M., & Santini, F. C. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00741-z · Cited by 20
A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials
Russo, C. D., Cappoli, N., & Navarra, P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02895-z · Cited by 20
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib
Wong, H. H., Bentley, H., Bulusu, V. R., Anyaegbu, G., Watkins, J. A., Horan, G., & Hatcher, H. M. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000994 · Cited by 20
Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma
Cai, L., Wang, J., Yan, J., Zeng, J., Zhu, L., Liang, J., Pan, C., Huang, X., Jin, J., Xu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.603671 · Cited by 20
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
Kalra, A., & Rashdan, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158417 · Cited by 19
Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
Qi, W.-L., Li, H.-Y., Wang, Y., Xu, L., Deng, J.-T., Zhang, X., Wang, Y.-X., & Meng, L.-H. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01015-0 · Cited by 19
Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Jiang, Z., Gu, Z., Yu, X.-M., Cheng, T., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447678 · Cited by 22
Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications
Elshimy, Y., Alkhatib, A. R., Atassi, B., & Mohammad, K. S. (2025) · Biomedicines · doi:10.3390/biomedicines13051160 · Cited by 21
Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?
Roeper, J., & Griesinger, F. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000495 · Cited by 19
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
Hu, J., Zhang, B., Yao, F., Fu, Y., Chen, D., Li, D., Du, N., Lizaso, A., Song, J., Zhang, L., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620935770 · Cited by 19
Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment
Janse, S., Janssen, E. M., Huwig, T., Roy, U. B., Ferris, A. A., Presley, C. J., & Bridges, J. F. P. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1888707 · Cited by 19
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
Naik, J., Beavers, N., Nilsson, F. O. L., Iadeluca, L. L., & Lowry, C. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00807-7 · Cited by 19
A narrative review of antibody–drug conjugates in EGFR-mutated non-small cell lung cancer
Hsu, R. C., & Benjamin, D. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252652 · Cited by 19
Advances in Personalized Oncology
Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., & Friedlaender, A. (2024) · Cancers · doi:10.3390/cancers16162862 · Cited by 19
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F. A., Adib, E., Cheung, J. M., Lin, J. J., Liu, Y., Lin, S. H., Parikh, K., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1379 · Cited by 19
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 22
A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib
Lin, H., Ren, G., & Liang, X. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.011 · Cited by 19
Brain metastasis in pancreatic cancer
Sasaki, T., Sato, T., Nakai, Y., Sasahira, N., Isayama, H., & Koike, K. (2019) · Medicine · doi:10.1097/md.0000000000014227 · Cited by 19
Current status of clinical proteogenomics in lung cancer
Nishimura, T., Nakamura, H., Végvári, Á., Marko‐Varga, G., Furuya, N., & Saji, H. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1654861 · Cited by 20
New generation anaplastic lymphoma kinase inhibitors
Delmonte, A., Burgio, M. A., Verlicchi, A., Bronte, G., Cravero, P., Ulivi, P., Martinelli, G., & Crinò, L. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.14 · Cited by 19
Functional and clinical significance of ROR1 in lung adenocarcinoma
Schiavone, G., Epistolio, S., Martin, V., Molinari, F., Barizzi, J., Mazzucchelli, L., Frattini, M., & Wannesson, L. (2020) · BMC Cancer · doi:10.1186/s12885-020-07587-6 · Cited by 19
Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody
Jin, S., Wang, H., Liu, X., Deng, Y., Yu, Y., Xu, P., Shou, J., Pan, H., Li, H., Zhou, X., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.679130 · Cited by 21
Alectinib
Herden, M., & Waller, C. F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_17 · Cited by 20
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
Yin, K., Feng, H., Li, L., Chen, Y., Xie, Z., Lv, Z., Guo, W., Lu, D., Yang, X., Yan, W., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13271 · Cited by 19
Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis
Dong, J., Li, L., Deng, T., Song, H., Zhang, S., & Zhong, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1361443 · Cited by 18
CT Characteristics of Non–Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis
Kim, T., Woo, S., Yoon, S. H., Halpenny, D. F., Han, S., & Suh, C. H. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21485 · Cited by 20
Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase–rearranged lung adenocarcinoma
Matsuura, Y., Ninomiya, H., Ichinose, J., Nakao, M., Okumura, S., Nishio, M., & Mun, M. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.09.120 · Cited by 18
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
Elsayed, M., Bozorgmehr, F., Kazdal, D. N., Volckmar, A., Sültmann, H., Fischer, J. R., Kriegsmann, M., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670483 · Cited by 18
Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
Harvey, M. J., Cunningham, R., Sawchyn, B., Montesion, M., Reddy, P., McBride, A., & Chawla, A. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00540 · Cited by 18
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies
Li, M., Garrison, L. P., Lee, W., Kowal, S. L., Wong, W. B., & Veenstra, D. L. (2022) · Value in Health · doi:10.1016/j.jval.2022.05.014 · Cited by 18
Personalized treatment for patients with lung cancer
Schüler, M., Bölükbas, S., Darwiche, K., Theegarten, D., Herrmann, K., & Stuschke, M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0012 · Cited by 20
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Zhong, J., Bai, H., Wang, Z., Duan, J., Zhuang, W., Wang, D., Wan, R., Xu, J., Fei, K., Ma, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0976-4 · Cited by 19
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review
Chen, J., Xu, C., Lv, J., Lu, W., Zhang, Y., Wang, D., & Song, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-566 · Cited by 18
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
Wang, M., Slatter, S., Sussell, J. A., Lin, C.-W., Ogale, S. S., Datta, D., Butte, A. J., Bazhenova, L. A., & Rudrapatna, V. A. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00973-7 · Cited by 18
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Kahraman, S., Karakaya, S., Ma, K., Göksu, S. S., Öztürk, A., İşleyen, Z. S., Hamdard, J., Yildirim, S., Doğan, T., Işık, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56046-w · Cited by 18
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer
Kareff, S. A., Han, S., Haaland, B. A., Jani, C., Kohli, R., Aguiar, P. N., Huang, Y., Soo, R. A., Rodríguez-Pérez, Á., García‐Foncillas, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.13938 · Cited by 18
ASCO update: lung cancer
Absenger, G., Terzic, J. A., & Bezan, A. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0373-x · Cited by 18
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Mezquita, L., & Planchard, D. (2018) · Cancer Management and Research · doi:10.2147/cmar.s129963 · Cited by 19
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
Heeke, S., Hofman, V., Long-Mira, É., Lespinet‐Fabre, V., Lalvée, S., Bordone, O., Ribeyre, C., Tanga, V., Benzaquen, J., Leroy, S., et al. (2018) · Cancers · doi:10.3390/cancers10040088 · Cited by 18
Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody
Wu, Z., Fournel, L., Städler, N., Liu, J., Boullier, A., Hoyeau, N., Fléjou, J. F., Duchatelle, V., Djebrani‐Oussedik, N., Agopiantz, M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.007 · Cited by 19
Targeting Molecular Pathways in Intracranial Metastatic Disease
Venur, V. A., Cohen, J. V., & Brastianos, P. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00099 · Cited by 18
Targeted Therapies in Non-small-Cell Lung Cancer
Hill, A., Gupta, R. V., Zhao, D., Vankina, R., Amanam, I. U., & Salgia, R. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_1 · Cited by 18
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Karachaliou, N., Bruno, M. F., Bracht, J. W. P., & Rosell, R. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s174548 · Cited by 18
Self-citation
Predictors of radiation necrosis in long-term survivors after Gamma Knife stereotactic radiosurgery for brain metastases
Siddiqui, Z. A., Squires, B. S., Johnson, M. D., Baschnagel, A. M., Chen, P. Y., Krauss, D. J., Olson, R. E., Meyer, K., & Grills, I. S. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz067 · Cited by 18
Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
Bylicki, O., Paleiron, N., Assié, J., & CHOUAID, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s219959 · Cited by 19
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Waterhouse, D. M., Espirito, J. L., Chioda, M. D., Baidoo, B., Mardekian, J., Robert, N. J., & Masters, E. T. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00207-6 · Cited by 18
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
Reyes, R., & Reguart, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-780 · Cited by 18
ERO1L promotes NSCLC development by modulating cell cycle‐related molecules
Shi, X., Wu, J., Liu, Y., Jiang, Y., Zhi, C., & Li, J. (2020) · Cell Biology International · doi:10.1002/cbin.11454 · Cited by 18
Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options
Huang, L., Jiang, X.-L., Liang, H., Li, J., Chin, L., Wei, J., Wang, R., Cai, J., Xiong, Q., Wang, L.-T., et al. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00197-9 · Cited by 18
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
Shafie, R. A. E., Seidensaal, K., Bozorgmehr, F., Kazdal, D. N., Eichkorn, T., Elshiaty, M., Weber, D., Allgäuer, M., König, L., Lang, K., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100161 · Cited by 18

Authors: Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
Affiliations: F. Hoffmann-La Roche AG (CH)
ORCID: Peters, Solange
Camidge, D. Ross
Shaw, Alice T.
Gadgeel, Shirish
Ahn, Jin S.
Kim, Dong-Wan
Ou, Sai-Hong I.
Rosell, Rafael
Mitry, Emmanuel
Balas, Bogdana
Morcos, Peter N.
Mok, Tony
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-08-31
Volume: 377
Issue: 9
Pages: 829-838
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1704795
OpenAlex: W2624310346
Cited by: 2,527
References: 14
Citations by year: 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
FWCI: 218.03
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
SERVAL (Université de Lausanne) (publishedVersion, other-oa)
Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
IRIS (submittedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Ariad Pharmaceuticals
Celgene
F. Hoffmann-La Roche
Array BioPharma
Regeneron Pharmaceuticals
Taiho Pharmaceutical
Les Laboratories Pierre Fabre
Clovis Oncology
G1 Therapeutics
Eisai
Genentech
EMD Serono
Ignyta
Loxo Oncology
Foundation Medicine
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
MeSH terms: Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks